Replacement Collaboration Compound definition

Replacement Collaboration Compound or “Replacement Product” means any Collaboration Compound or Product selected by BI for further Development and/or Commercialization which is aimed to replace a Collaboration Compound or Product for which BI, at the same time, definitively terminates further Development and/or Commercialization thereof.
Replacement Collaboration Compound means a GTx SARM Compound that is selected to replace a Collaboration Compound then under development as described in Section 4.6.

Examples of Replacement Collaboration Compound in a sentence

  • With the exception of this post-SoPD meeting, the meetings of the Program Steering Committee shall be suspended until the earlier of (a) the Filing with the U.S. Food and Drug Administration of the first Investigational New Drug Application for the first Replacement Collaboration Compound for ZP2929, or (b) the first ethical committee approval of a Phase I Clinical trial for the first Replacement Collaboration Compound for ZP2929.

  • The JDC will review and approve, with respect to GTx/Ortho Development, the addition of new indications, the ceasing of Development of Andarine, and the addition of a Replacement Collaboration Compound or an Additional Compound.

  • Other than the milestone payments recited in Section 3.2, Ortho shall not be obligated to make any other milestone payments in connection with Andarine, a Replacement Collaboration Compound, or any Additional Collaboration Compound.

  • It is understood that in no event shall Ortho be obligated to make the payment due pursuant to this Section 3.2 on any milestone more than once with respect to the same Collaboration Compound (or its "Replacement Collaboration Compound") regardless of the number of different forms or formulations of the Collaboration Compound that are developed[ * ].

  • Furthermore, if the Ortho determines that further Development of Andarine or an Additional Collaboration Compound, if any, is not desirable, then it may select another Collaboration Compound to replace Andarine or such Additional Collaboration Compound (and such replacement compound shall be a "Replacement Collaboration Compound").

  • In either of the foregoing events, within forty-five (45) calendar days after the selection of such Additional Collaboration Compound or Replacement Collaboration Compound, then Ortho shall update the then-current Development Plan and Development Budget to provide for Development of such compound.

Related to Replacement Collaboration Compound

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Licensed Compounds means: (a) Research Program Active Compounds; (b) Novartis Active Compounds; (c) salts, hydrates, solvates, esters, metabolites, intermediates, stereoisomers and polymorphs of Research Program Active Compounds or Novartis Active Compounds; and (d) prodrugs of Research Program Active Compounds or Novartis Active Compounds (any of the foregoing, a “Licensed Compound”).

  • Licensed Compound means [***].

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Collaboration Product means a pharmaceutical product containing or comprising Compound in any dosage form alone, or in combination with, one or more other pharmaceutically active ingredients, and any and all Improvements thereto.

  • Collaboration Patent Rights means Patent Rights claiming Collaboration Know-How.

  • Replacement Candidate means any Candidate Introduced by the Agency to the Client to fill the Engagement following the Introduction of another Candidate whose Engagement either did not commence or was terminated during the first 12 weeks of the Engagement;

  • Compounds means any or all of the following chemicals, as the context requires:

  • Collaboration Know-How means all Know-How conceived, discovered, developed or otherwise made by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing (solely or jointly by or on behalf of a particular Party or any of its Affiliates or permitted subcontractors of any of the foregoing) in the course of [***].

  • Collaboration Patents means any and all Patents that claim or cover any of the Collaboration Know-How.

  • Replacement Product means electric generating capacity, capacity-related benefits, environmental attributes, Energy or other electric products from a generation resource other than the Facility that are provided or delivered to replace or substitute for Contract Capacity or Storage Capacity (or any Capacity-Related Benefit, Environmental Attribute, Other Electric Product, Contract Energy, or Storage Energy associated therewith), in each case, in whole or in part, pursuant to Section 4.6.

  • Massive Multiauthor Collaboration Site (or “MMC Site”) means any World Wide Web server that publishes copyrightable works and also provides prominent facilities for anybody to edit those works. A public wiki that anybody can edit is an example of such a server. A “Massive Multiauthor Collaboration” (or “MMC”) contained in the site means any set of copyrightable works thus published on the MMC site.

  • Exempt compound means the same as defined in Rule 2.

  • Collaborative drug therapy management means participation by an authorized pharmacist and a physician in the management of drug therapy pursuant to a written community practice protocol or a written hospital practice protocol.

  • Compound means the taking of two or more ingredients and fabricating them into a single

  • Collaboration IP means Collaboration Know-How and Collaboration Patents.

  • Program Patent Rights means any Patent Rights that contain one or more claims that cover Program Inventions.

  • Development Site means any parcel or lot on which exists or which is intended for building development other than the following:

  • Existing Product means any formulation of the same product category and form sold, supplied, manufactured, or offered for sale in California prior to the following dates, or any subsequently introduced identical formulation:

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Phase I Clinical Trial means a human clinical trial that is intended to initially evaluate the safety and/or pharmacological effect of a Product in subjects or that would otherwise satisfy requirements of 21 C.F.R. 312.21(a), or its foreign equivalent.

  • Licensed Product means a product or part of a product in the Licensed Field of Use: (A) the making, using, importing or selling of which, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent; or (B) which is made with, uses or incorporates any Technology.

  • Manufacturing Technology means any and all patents, patent applications, know-how, and all intellectual property rights associated therewith that are owned or controlled by Licensor, and including all tangible embodiments thereof, that are necessary or useful for the manufacture of adeno-associated viruses, adeno-associated virus vectors, research or commercial reagents related thereto, Licensed Products, or other products, including manufacturing processes, technical information relating to the methods of manufacture, protocols, standard operating procedures, batch records, assays, formulations, quality control data, specifications, scale up, any and all improvements, modifications, and changes thereto, and any and all activities associated with such manufacture. Any and all chemistry, manufacturing, and controls (CMC), drug master files (DMFs), or similar materials provided to regulatory authorities and the information contained therein are deemed Manufacturing Technology.